Latest Breaking News On - Persist 2 study - Page 1 : comparemela.com

Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.

Data with pacritinibPatients with myelofibrosisMf cancerPrimary myelofibrosisJak inhibitorsJak inhibitionNovel therapyPersist 2 trialPersist 2 studyIrak signalingClinical trialsPatient selectionPatient eligibilityPacifica trialPacifica study